155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT. (December 2022)

Record Type:: Journal Article
Title:: 155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT. (December 2022)
Main Title:: 155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT
Authors:: Klinghammer, K.
Saba, N.F.
Castelluci, E.
Colevas, A.D.
Rutkowski, T.
Greil, R.
Thurner, D.
Müller-Richter, U.
Di Giacomo, A.M.
Grewal, J.
Ottensmeier, C.H.H.
Atasoy, A.
Shpyro, S.
Brück, P.
Dias, J.
Ganser, C.
Türeci, Ö.
Sahin, U.
Abstract:
Is Part Of:: Immuno-oncology technology. Volume 16(2022)Supplement 1
Journal:: Immuno-oncology technology
Issue:: Volume 16(2022)Supplement 1
Issue Display:: Volume 16, Issue 1 (2022)
Year:: 2022
Volume:: 16
Issue:: 1
Issue Sort Value:: 2022-0016-0001-0000
Page Start:
Page End:
Publication Date:: 2022-12
Subjects:: Cancer -- Immunotherapy -- Periodicals
616.994061
Journal URLs:: https://www.esmoiotech.org/issues ↗
http://www.sciencedirect.com/ ↗
DOI:: 10.1016/j.iotech.2022.100267 ↗
Languages:: English
ISSNs:: 2590-0188
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 24744.xml